Advanced

Analys av HER2 i bröstcancer kvalitetssäkrad. Viktig behandlingsprediktiv och prognostisk faktor.

Fernö, Mårten LU ; Haglund, Monica; Bendahl, Pär-Ola LU ; Olsson, Hans and Rydén, Lisa LU (2008) In Läkartidningen 105(32-33). p.2181-2184
Abstract
Human epidermal growth factor receptor 2 (HER2) is overexpressed and/or

amplified in 15-20% of all breast cancers, and is associated with an aggressive tumour type

with impaired prognosis and a predictive marker for trastuzumab treatment. HER2 status can

be determined by immunohistochemistry (IHC) at protein level and by fluorescence in situ

hybridisation (FISH) analysing gene amplification, and it is recommended that it should be

performed in all primary breast cancers. In a quality control study the reproducibility of HER2 status was assessed by distributing eleven breast tumours prepared on a tissue microarray to 25 pathology laboratories in Sweden in 2005 and 2006. The concordance between... (More)
Human epidermal growth factor receptor 2 (HER2) is overexpressed and/or

amplified in 15-20% of all breast cancers, and is associated with an aggressive tumour type

with impaired prognosis and a predictive marker for trastuzumab treatment. HER2 status can

be determined by immunohistochemistry (IHC) at protein level and by fluorescence in situ

hybridisation (FISH) analysing gene amplification, and it is recommended that it should be

performed in all primary breast cancers. In a quality control study the reproducibility of HER2 status was assessed by distributing eleven breast tumours prepared on a tissue microarray to 25 pathology laboratories in Sweden in 2005 and 2006. The concordance between the laboratories indicated good reproducibility for IHC 2005 (kappa value 0.79) and very good reproducibility for 2006 (kappa value 0.86). The corresponding reproducibility for FISH was very good on both occasions (kappa value 0.92 and 0.96 respectively). A questionnaire indicated that 90% of all primary breast cancers diagnosed in Sweden in 2006 were tested for HER2 status. By way of summary, HER2 status is now implemented in clinical routine diagnostics in Sweden, and the present reproducibility study supports a high quality of testing. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Breast Neoplasms: drug therapy, Breast Neoplasms: metabolism, Breast Neoplasms: pathology, Immunohistochemistry: standards, In Situ Hybridization, Fluorescence: standards, Receptor, erbB-2: analysis, erbB-2: metabolism, Biological: analysis, Tumor Markers, Breast Neoplasms: diagnosis, Monoclonal: therapeutic use, Antibodies, Antineoplastic Agents: therapeutic use
in
Läkartidningen
volume
105
issue
32-33
pages
2181 - 2184
publisher
Sveriges Läkarförbund
external identifiers
  • pmid:18780693
  • scopus:49649103523
ISSN
0023-7205
language
Swedish
LU publication?
yes
id
b45c9eb0-6ea7-45f7-8d78-2b19d94577cf (old id 1243228)
alternative location
http://www.ncbi.nlm.nih.gov/pubmed/18780693?dopt=Abstract
http://ltarkiv.lakartidningen.se/artNo35403
date added to LUP
2008-10-07 13:34:47
date last changed
2017-01-01 07:43:46
@article{b45c9eb0-6ea7-45f7-8d78-2b19d94577cf,
  abstract     = {Human epidermal growth factor receptor 2 (HER2) is overexpressed and/or<br/><br>
amplified in 15-20% of all breast cancers, and is associated with an aggressive tumour type<br/><br>
with impaired prognosis and a predictive marker for trastuzumab treatment. HER2 status can<br/><br>
be determined by immunohistochemistry (IHC) at protein level and by fluorescence in situ<br/><br>
hybridisation (FISH) analysing gene amplification, and it is recommended that it should be<br/><br>
performed in all primary breast cancers. In a quality control study the reproducibility of HER2 status was assessed by distributing eleven breast tumours prepared on a tissue microarray to 25 pathology laboratories in Sweden in 2005 and 2006. The concordance between the laboratories indicated good reproducibility for IHC 2005 (kappa value 0.79) and very good reproducibility for 2006 (kappa value 0.86). The corresponding reproducibility for FISH was very good on both occasions (kappa value 0.92 and 0.96 respectively). A questionnaire indicated that 90% of all primary breast cancers diagnosed in Sweden in 2006 were tested for HER2 status. By way of summary, HER2 status is now implemented in clinical routine diagnostics in Sweden, and the present reproducibility study supports a high quality of testing.},
  author       = {Fernö, Mårten and Haglund, Monica and Bendahl, Pär-Ola and Olsson, Hans and Rydén, Lisa},
  issn         = {0023-7205},
  keyword      = {Breast Neoplasms: drug therapy,Breast Neoplasms: metabolism,Breast Neoplasms: pathology,Immunohistochemistry: standards,In Situ Hybridization,Fluorescence: standards,Receptor,erbB-2: analysis,erbB-2: metabolism,Biological: analysis,Tumor Markers,Breast Neoplasms: diagnosis,Monoclonal: therapeutic use,Antibodies,Antineoplastic Agents: therapeutic use},
  language     = {swe},
  number       = {32-33},
  pages        = {2181--2184},
  publisher    = {Sveriges Läkarförbund},
  series       = {Läkartidningen},
  title        = {Analys av HER2 i bröstcancer kvalitetssäkrad. Viktig behandlingsprediktiv och prognostisk faktor.},
  volume       = {105},
  year         = {2008},
}